Media headlines about WuXi PharmaTech (Cayman) (NYSE:WX) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. WuXi PharmaTech (Cayman) earned a daily sentiment score of 0.12 on Accern’s scale. Accern also assigned news coverage about the medical research company an impact score of 46.6048507191468 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Here are some of the media headlines that may have effected Accern’s rankings:

COPYRIGHT VIOLATION NOTICE: “WuXi PharmaTech (Cayman) (WX) Earns Daily Coverage Optimism Score of 0.12” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/09/04/wuxi-pharmatech-cayman-wx-earns-daily-coverage-optimism-score-of-0-12.html.

WuXi PharmaTech (Cayman) Company Profile

WuXi PharmaTech (Cayman) Inc is a pharmaceutical, biotechnology and medical device research and development (R&D) services company, with operations in China and the United States. The Company provides a portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process to its customers.

Receive News & Stock Ratings for WuXi PharmaTech (Cayman) Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WuXi PharmaTech (Cayman) Inc. and related stocks with our FREE daily email newsletter.